Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acamprosate - Confluence Pharmaceuticals

Drug Profile

Acamprosate - Confluence Pharmaceuticals

Alternative Names: AOP 2020; Campral; SF 679/SF 775; SF 999

Latest Information Update: 25 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Confluence Pharmaceuticals
  • Developer Cincinnati Children's Hospital Medical Center; Indiana University; Rush University
  • Class Alkanesulfonic acids; Behavioural disorder therapies; Drug withdrawal therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists; Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Fragile X syndrome
  • Phase II Autistic disorder

Most Recent Events

  • 06 Feb 2018 Chemical structure information added
  • 23 Jan 2018 Phase II/III development is ongoing for Fragile X syndrome and Autistic disorder in USA (NCT01911455) (NCT01813318)
  • 23 Mar 2015 Confluence Pharmaceuticals and AOP Orphan Pharmaceuticals enter into an agreement to co-develop and market acamprosate for fragile X syndrome in Europe and the Middle East
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top